Teneligliptin linked to Bullous Pemphigoid: IPC Drug Safety Alert

The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of June, has revealed that the popular antidiabetic drug Teneligliptin is linked with adverse drug reactions (ADRs) named Bullous Pemphigoid.

This came after a preliminary analysis of Adverse Drug Reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.

Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus (T2DM) in adults along with diet and exercise. The mechanism of Teneligliptin is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.

For more details, check out the link given below:

Drug Safety Alert: Indian Pharmacopoeia Commission Flags Adverse Reactions Linked To Teneligliptin